Navigation Links
Malaria Drug Doesn't Boost Survival Odds With Prion Diseases
Date:3/11/2009

Oral quinacrine showed no benefit for brain-wasting disorders such as Creutzfeldt-Jakob

WEDNESDAY, March 11 (HealthDay News) -- The drug quinacrine doesn't prolong survival of patients with brain-wasting prion diseases such as Creutzfeldt-Jakob disease (CJD), British researchers say.

Currently, there is no way to prevent or reverse the progression of prion diseases. However, quinacrine -- an oral drug used to treat malaria and some forms of arthritis -- has been shown to be effective in treating prion-infected mouse cells.

This study included 107 patients, aged 12 and older, with prion disease. They underwent neurological assessments and clinical exams at the start of the study and again one, two, four and six months later. After that, the patients were examined every three months.

Some patients started taking 300 milligrams of quinacrine per day at the start of the study, one group started taking the drug later in the study, and others didn't take quinacrine.

During the study, 78 patients died, including 26 who took the drug immediately and 52 who initially took no quinacrine or delayed treatment.

After adjusting for factors such as disease severity and type of prion disease, the researchers found no significant difference in survival rates between those who took quinacrine and those who initially didn't take the drug.

The study was released online and was expected to be published in the April print issue of The Lancet Neurology.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about prion diseases.



-- Robert Preidt



SOURCE: The Lancet Neurology, news release, March 10, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Kenyan malaria success strengthens call for free insecticide-treated nets for all
2. MDS Pharma Services Wins Award for Management of Global Malaria Trial
3. How adhesive protein causes malaria
4. Malaria product portfolio would benefit from greater cohesion amongst stakeholders
5. USAID Announces First Malaria Communities Program Grants
6. Collaborative Drug Discovery, Inc. and St. Jude Childrens Research Hospital Make Malaria Research Data Available to Speed Drug Development
7. World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths
8. Sanofi Pasteur and Institut Pasteur Team up Against Malaria
9. Bill and Melinda Gates Call for New Global Commitment to Chart a Course for Malaria Eradication
10. Malaria No More and Sumitomo Chemical Help Protect 1.4 Million Kids from Malaria
11. Malaria Vaccine Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Malaria Drug Doesn't Boost Survival Odds With Prion Diseases
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement ... Vice President of North American Capital Sales at HTG Molecular . ... in the commercialization of the HTG EdgeSeq system and associated reagents in North America. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, ... stem (iPS) cells and other difficult to transfect cells, announces its launch of ... PluriQ™ G9™ Gene Editing System is a complete system for culturing and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
Breaking Medicine Technology: